An Early Look at a Novel Intranasal Loop Diuretic

A common cause of decompensated heart failure is decreased oral diuretic absorption due to gut edema, often requiring inpatient admission for intravenous diuretics. In this open-label, randomized, controlled, crossover trial, researchers assessed the bioavailability of a novel bumetanide nasal spray compared with oral and intravenous bumetanide.

Sixty-eight healthy volunteers received treatment with oral, intranasal, and intravenous bumetanide, each separated by a 48-hour washout period, in one of four randomly assigned sequences. Serum and urine samples were obtained to measure pharmacokinetics and pharmacodynamics.

The bumetanide nasal spray had statistical bioequivalence to oral bumetanide (the primary endpoint) as well as more-rapid absor…